William Blair analyst Myles Minter has reiterated their bullish stance on ARGX stock, giving a Buy rating yesterday.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Myles Minter has given his Buy rating due to a combination of factors that highlight Argenx’s promising pipeline and strategic positioning in the market. The company’s recent R&D event showcased the potential of ARGX-119, a bivalent muscle-specific kinase (MuSK) agonist antibody, which is advancing into a registrational Phase III trial for congenital myasthenic syndromes (CMS). The preliminary data from the Phase Ib trial indicated significant improvements in the 6-minute walk test, suggesting a meaningful clinical benefit that could position ARGX-119 as a leader in this niche market.
Minter also emphasizes Argenx’s strategic diversification beyond its flagship product, Vyvgart, by advancing ARGX-119 and empasiprubart. This diversification is seen as a crucial step in reducing the company’s reliance on a single product, thereby enhancing its long-term growth prospects and supporting its transition towards becoming a large-cap pharmaceutical company. The focus on ultra-orphan indications like CMS, where ARGX-119 has a concentrated potential for success, further strengthens the company’s competitive edge and innovation-driven growth strategy.
According to TipRanks, Minter is a 5-star analyst with an average return of 22.9% and a 59.68% success rate. Minter covers the Healthcare sector, focusing on stocks such as Dianthus Therapeutics, Argenx Se, and Ionis Pharmaceuticals.
In another report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $887.00 price target.